BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 38621459)

  • 1. Anlotinib enhanced CD8
    Luo J; Cheng K; Ji X; Gao C; Zhu R; Chen J; Xue W; Huang Q; Xu Q
    Cancer Lett; 2024 Jun; 591():216892. PubMed ID: 38621459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma.
    Tang H; You T; Ge H; Gao J; Wang Y; Bai C; Sun Z; Han Q; Zhao RC
    Int Immunopharmacol; 2024 May; 133():112053. PubMed ID: 38615380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade.
    Chen L; Diao L; Yang Y; Yi X; Rodriguez BL; Li Y; Villalobos PA; Cascone T; Liu X; Tan L; Lorenzi PL; Huang A; Zhao Q; Peng D; Fradette JJ; Peng DH; Ungewiss C; Roybal J; Tong P; Oba J; Skoulidis F; Peng W; Carter BW; Gay CM; Fan Y; Class CA; Zhu J; Rodriguez-Canales J; Kawakami M; Byers LA; Woodman SE; Papadimitrakopoulou VA; Dmitrovsky E; Wang J; Ullrich SE; Wistuba II; Heymach JV; Qin FX; Gibbons DL
    Cancer Discov; 2018 Sep; 8(9):1156-1175. PubMed ID: 30012853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IR-780 Dye-based Targeting of Cancer-associated Fibroblasts Improves Cancer Immunotherapy by Increasing Intra-tumoral T Lymphocytes Infiltration.
    Yang W; Chen Z; Qu L; Zhang C; Chen H; Zheng J; Chen W; Tan X; Shi C
    Curr Cancer Drug Targets; 2024; 24(6):642-653. PubMed ID: 38310462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis.
    LaMarche NM; Hegde S; Park MD; Maier BB; Troncoso L; Le Berichel J; Hamon P; Belabed M; Mattiuz R; Hennequin C; Chin T; Reid AM; Reyes-Torres I; Nemeth E; Zhang R; Olson OC; Doroshow DB; Rohs NC; Gomez JE; Veluswamy R; Hall N; Venturini N; Ginhoux F; Liu Z; Buckup M; Figueiredo I; Roudko V; Miyake K; Karasuyama H; Gonzalez-Kozlova E; Gnjatic S; Passegué E; Kim-Schulze S; Brown BD; Hirsch FR; Kim BS; Marron TU; Merad M
    Nature; 2024 Jan; 625(7993):166-174. PubMed ID: 38057662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
    Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
    Front Immunol; 2021; 12():637146. PubMed ID: 34025646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. METTL14 regulates CD8
    Sun C; Wang J; Li H; Liu L; Lin Y; Zhang L; Zu X; Zhu Y; Shu Y; Shen D; Wang Q; Liu Y
    World J Surg Oncol; 2024 May; 22(1):128. PubMed ID: 38725005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanodrug modified with engineered cell membrane targets CDKs to activate aPD-L1 immunotherapy against liver metastasis of immune-desert colon cancer.
    Ding D; Liang R; Li T; Lan T; Li Y; Huang S; He G; Ren J; Li W; Zheng Z; Chen T; Fang J; Huang L; Shuai X; Wei B
    J Control Release; 2024 May; 369():309-324. PubMed ID: 38554771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCR6-positive circulating mucosal-associated invariant T cells can identify patients with non-small cell lung cancer responding to anti-PD-1 immunotherapy.
    Qu J; Wu B; Chen L; Wen Z; Fang L; Zheng J; Shen Q; Heng J; Zhou J; Zhou J
    J Exp Clin Cancer Res; 2024 May; 43(1):134. PubMed ID: 38698468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral CX3CR1
    Li C; Zhang Z; Cai Q; Zhao Q; Wu H; Li J; Liu Y; Zhao X; Liu J; Ping Y; Shan J; Yang S; Zhang Y
    Oncoimmunology; 2024; 13(1):2355684. PubMed ID: 38798746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SIRPG expression positively associates with an inflamed tumor microenvironment and response to PD-1 blockade.
    Luo L; Jiang M; Wu H; Liu Y; Wang H; Zhou C; Ren S; Chen X; Jiang T; Xu C
    Cancer Immunol Immunother; 2024 Jun; 73(8):147. PubMed ID: 38833156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Batf3
    Ziblat A; Horton BL; Higgs EF; Hatogai K; Martinez A; Shapiro JW; Kim DEC; Zha Y; Sweis RF; Gajewski TF
    Cell Rep; 2024 May; 43(5):114141. PubMed ID: 38656869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipopolysaccharide-Mediated Chronic Inflammation Promotes Tobacco Carcinogen-Induced Lung Cancer and Determines the Efficacy of Immunotherapy.
    Liu CH; Chen Z; Chen K; Liao FT; Chung CE; Liu X; Lin YC; Keohavong P; Leikauf GD; Di YP
    Cancer Res; 2021 Jan; 81(1):144-157. PubMed ID: 33122306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-VEGFR2-Interferon α Promotes the Infiltration of CD8+ T Cells in Colorectal Cancer by Upregulating the Expression of CCL5.
    Huang L; Gao R; Nan L; Qi J; Yang S; Shao S; Xie J; Pan M; Qiu T; Zhang J
    J Immunother; 2024 Jul-Aug 01; 47(6):195-204. PubMed ID: 38654631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism/Immunity Dual-Regulation Thermogels Potentiating Immunotherapy of Glioblastoma Through Lactate-Excretion Inhibition and PD-1/PD-L1 Blockade.
    Li T; Xu D; Ruan Z; Zhou J; Sun W; Rao B; Xu H
    Adv Sci (Weinh); 2024 May; 11(18):e2310163. PubMed ID: 38460167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAML promotes the antitumor role of tumor-resident CD8
    Hao Z; Xin Z; Chen Y; Shao Z; Lin W; Wu W; Lin M; Liu Q; Chen D; Wu D; Wu P
    Cancer Lett; 2024 May; 590():216839. PubMed ID: 38570084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Niraparib enhances antitumor immunity and contributes to the efficacy of PD-L1 blockade in cervical cancer.
    Chang J; Quan S; Tian S; Wang S; Li S; Guo Y; Yang T; Yang X
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):304. PubMed ID: 38869633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stabilizing Tumor-Resident Mast Cells Restores T-Cell Infiltration and Sensitizes Sarcomas to PD-L1 Inhibition.
    Panagi M; Mpekris F; Voutouri C; Hadjigeorgiou AG; Symeonidou C; Porfyriou E; Michael C; Stylianou A; Martin JD; Cabral H; Constantinidou A; Stylianopoulos T
    Clin Cancer Res; 2024 Jun; 30(11):2582-2597. PubMed ID: 38578281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation anti-PD-L1/IL-15 immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicity.
    Shi W; Liu N; Liu Z; Yang Y; Zeng Q; Wang Y; Song L; Hu F; Fu J; Chen J; Wu M; Zhou L; Zhu F; Gong L; Zhu J; Jiang L; Lu H
    Cell Rep Med; 2024 May; 5(5):101531. PubMed ID: 38697105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing personalized responses to anti-PD-1 treatment using patient-derived lung tumor-on-chip.
    Veith I; Nurmik M; Mencattini A; Damei I; Lansche C; Brosseau S; Gropplero G; Corgnac S; Filippi J; Poté N; Guenzi E; Chassac A; Mordant P; Tosello J; Sedlik C; Piaggio E; Girard N; Camonis J; Shirvani H; Mami-Chouaib F; Mechta-Grigoriou F; Descroix S; Martinelli E; Zalcman G; Parrini MC
    Cell Rep Med; 2024 May; 5(5):101549. PubMed ID: 38703767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.